Clinical Trial Update: Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy of [18F]PSMA-1007 PET/CT in biochemically recurrent prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: ABX advanced biochemical compounds GmbH | Conditions: Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Status: COMPLETED